Biopharma’s highest-paid CEOs; John Carroll’s Q2 analysis; Merck to buy Verona Pharma for $10B; and morenews2025-07-12T10:00:24+00:00July 12th, 2025|Endpoints News|
Apple Tree says its biotechs face ‘imminent collapse’; Advocates urge J&J to proceed with eye gene therapy; AbbVie buys in vivo CAR-T maker Capstan; and morenews2025-07-05T10:00:03+00:00July 5th, 2025|Endpoints News|
Sources say FDA commissioner sought rejection of KalVista’s rare disease drug; FDA looks into Sarepta’s Duchenne therapy after deaths; and morenews2025-06-28T10:00:05+00:00June 28th, 2025|Endpoints News|
FDA unveils new pilot program; Sage finds a buyer; Eli Lilly to acquire Verve; and morenews2025-06-21T10:00:26+00:00June 21st, 2025|Endpoints News|
RFK removes all ACIP members, names new ones; National Resilience to close six sites; Deals and financing recap of the weeknews2025-06-14T10:00:04+00:00June 14th, 2025|Endpoints News|
Highlights from #ASCO25; Biotech’s icy market; Sanofi’s $9B acquisition; and morenews2025-06-07T10:00:28+00:00June 7th, 2025|Endpoints News|
Patient dies in Rocket gene therapy trial; Lilly’s $1B deal for a non-opioid pain biotech; A new dawn for psychedelics?; and morenews2025-05-31T10:00:19+00:00May 31st, 2025|Endpoints News|
Analyzing the Endpoints 100; ‘Most favored nation’ targets revealed; Biotech slump makes leases a liability; and morenews2025-05-24T10:00:30+00:00May 24th, 2025|Endpoints News|
What we know about ‘most favored nation’; GSK’s $1.2B MASH deal; Bayer details staff cuts; and morenews2025-05-17T10:00:13+00:00May 17th, 2025|Endpoints News|
Makary names Vinay Prasad CBER chief; Q1 earnings report; More on “Most Favored Nations”; and morenews2025-05-10T10:00:49+00:00May 10th, 2025|Endpoints News|
